Onlife® - Quellennachweise und weiterführende Literatur

Aus rechtlichen Gründen weisen wir darauf hin: Die Informationen, die bzgl. der Wirkungen der Nähr- und Inhaltsstoffe in Onlife® gegeben werden, wurden sorgfältig recherchiert und aus Studien erarbeitet. Sie dienen der Zusammenfassung wissenschaftlicher Erkenntnisse und nicht der Konstatierung einer entsprechenden Wirksamkeit des Produkts. Die Studienergebnisse können nachgelesen werden:

(1) Bisogno T, Di Marzo V. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets (2010)
(2) Cocito D., Peci E., Ciaramitaro P., Merola A., Leonardo L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Research and Treatment. 2014
(3) Di Cesare Mannelli L., D‘Agostino G., Pacini A., et al. Palmitoylethanolamide is a disease- modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators of Inflammation. 2013
(4) Di Cesare Mannelli L, Pacini A, Corti F, Boccella S, Luongo L, Esposito E, et al. Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity. PLoS One. 2015;10
(5) Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U S A. 1995;92: 3376–80
(6) Finocchiaro C, Segre O, Fadda M, Monge T, Scigliano M, Schena M, Tinivella M, Tiozzo E, Catalano MG, Pugliese M. et al. Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr. 2012;108: 327–333
(7) Ghoreishi Z, Esfahani A, Djazayeri A, et al.: (2012) Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized double-blind placebo controlled trial. BMC Cancer 12:355
(8) Gil A. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother. 2002; 56:388–96. 
(9) Hesselink: New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide. The Open Pain Journal, 2012, 5, 12-23
(10) Hesselink J. M.: Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. International Medical Case Reports Journal. 2013;6(1):49–53.
(11) Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor perox- isome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15-9
(12) Mazza M, Pomponi M, Janiri L, Bria P, Mazza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2007;31:12–26
(13) Park SB, Lin CS, Krishnan AV et al. Longterm neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011; 16: 708–716
Postma TJ, Vermorken JB, Liefting AJ et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489–494
(14) Reyes-Gibby CC, Morrow PK, Buzdar A et al. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain 2009; 10: 1146–1150
(15) Shapiro H. Could n-3 polyunsaturated fatty acids reduce pathological pain by direct actions on the nervous system? Prostaglandins, leukotrienes, and essential fatty acids. 2003;68(3):219–24
(16) Skaper SD, Facci GP. Mast cells, glia and neuroinflammation: partners in crime? Immunology. 2014;141: 314–27.
(17) Skaper S. D., Facci L., Fusco M., Della Valle M. F., Zusso M., Costa B., et al. (2014). Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.
(18) Truini A., Biasiotta A., Di Stefano G., et al. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS & Neurological Disorders – Drug Targets. 2011;10(8):916–920.
(19) Visioli F, Giordano E, Nicod NM, Davalos A. Molecular targets of omega 3 and conjugated linoleic Fatty acids - „micromanaging“ cellular response. Front Physiol. 2012; 3:42 Inflammopharmacology 22, 79–94.
(20) Zaiss et al.: Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO Oncol Res Treat, 2021; 44(11): 613-621.

(21) J Clin Oncol. 2014 Jun 20;32(18):1941-67: Prevention and management of chemotherapy- induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.